全身免疫炎症指数及躯体化症状评分对首发心梗PCI术后发生院内主要不良心血管事件的预测价值
|
|
郑梦奕, 毛家亮, 邹治国, 张瑞雷, 张厚, 李世光
|
Predictive value of systemic immune inflammation index and somatic symptom scale-China in the occurrence of in-hospital major adverse cardiovascular events after first-episode of acute myocardial infarction undergoing PCI
|
|
ZHENG Mengyi, MAO Jialiang, ZOU Zhiguo, ZHANG Ruilei, ZHANG Hou, LI Shiguang
|
|
表1 非MACEs组与MACEs组患者临床资料比较
|
Tab 1 Comparison of clinical data between non-MACEs group and MACEs group
|
|
| Clinical data | MACEs group (n=203) | non-MACEs group (n=102) | P value |
|---|
| Age/year | 68.13±19.92 | 53.97±12.02 | 0.010 | | Female/n(%) | 63 (31.0) | 13 (12.8) | 0.000 | | Hospital stay/d | 11.78±5.36 | 9.11±2.27 | 0.010 | | SII/(×109·L-1) | 1 925.86±286.23 | 934.23±45.96 | 0.010 | | SSS-CN | 38.57±11.78 | 23.30±9.59 | 0.000 | | SS | 15.56±8.36 | 12.07±6.07 | 0.000 | | Multiple vessel lesions/n(%) | 179 (88.2) | 67 (65.7) | 0.010 | | NT-Pro BNP/(ng·L-1) | 2 033.53±301.36 | 358.49±149.84 | 0.000 | | TnI/(μg·L-1) | 42.46±76.53 | 18.26±80.63 | 0.011 | | Killip rating≥Ⅱ/n(%) | 102 (50.2) | 20 (19.6) | 0.000 | | Neutrophil /(×109·L-1) | 7.94±3.47 | 6.76±2.83 | 0.002 | | Lymphocyte/(×109·L-1) | 1.52±0.98 | 1.77±0.79 | 0.027 | | Platelet/(×109·L-1) | 222.17±56.93 | 245.23±75.56 | 0.039 | | Usage of NE/n(%) | 77 (37.9) | 4 (3.9) | 0.000 | | Admitted SBP/mmHg | 129.33±23.41 | 136.83±23.90 | 0.040 | | Admitted DBP/mmHg | 79.81±15.73 | 86.41±17.05 | 0.000 | | Diabetes/n(%) | 79 (38.9) | 26 (25.4) | 0.005 | | Apoplexy/n(%) | 46 (22.7) | 11 (10.8) | 0.002 | | Left main trunk/n(%) | 37 (18.2) | 15 (14.7) | 0.737 | | CK/(U·L-1) | 840.00±99.76 | 706.00±119.52 | 0.405 | | CK-MB/(U·L-1) | 80.72±8.03 | 79.10±13.43 | 0.912 | | Hypertension/n(%) | 141 (69.5) | 65 (63.7) | 0.066 | | Hyperlipidemia/n(%) | 43 (21.2) | 30 (29.4) | 0.209 |
|
|
|